The course of gastric cancer following surgery is associated with genetic variations of the interleukin-1 receptor antagonist and interleukin-1β.

Gastric Cancer 2015 Jan 21;18(1):77-83. Epub 2014 Feb 21.

Institute for Microbiology and Hygiene, Charité University Medicine Berlin, Hindenburgdamm 27, 12203, Berlin, Germany.

Background: Inflammation, especially the cytokine response of the IL-1 family, has been shown to influence susceptibility to gastric cancer. In addition, several other pro-inflammatory cytokines have been demonstrated to influence metastasis and resistance to chemotherapy. Therefore, genetic variations within these genes may not only affect susceptibility but also influence the outcome of gastric cancer patients. A limited number of studies showed indeed an association of IL-1β and IL-1RN variations with survival of gastric cancer patients. However, results are inconsistent, possibly because of different patient cohorts and different therapies.

Methods: In this retrospective cohort study we genotyped 154 patients with gastric cancer for IL-1β and IL-1RN variations. Patients had undergone pathologically proven R0 resection and had received no additional adjuvant treatment.

Results: We show here a protective association with disease-free survival for both heterozygous genotypes, IL-1β SNP C-511T (rs16944) and IL-1RN VNTR. The combination of both heterozygous genotypes is the strongest predictor independent of UICC stage.

Conclusion: Genetic variations in the IL-1β and IL-1RN genes influence disease progression in gastric cancer. Screening for these genetic variations might help to stratify therapies for gastric cancer patients in the future.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10120-014-0349-zDOI Listing
January 2015
6 Reads

Publication Analysis

Top Keywords

gastric cancer
28
genetic variations
16
il-1β il-1rn
12
cancer patients
12
il-1rn variations
8
heterozygous genotypes
8
cancer
7
variations
6
gastric
6
patients
5
undergone pathologically
4
patients undergone
4
variations patients
4
patients gastric
4
cancer il-1β
4
pathologically proven
4
resection received
4
received additional
4
154 patients
4
additional adjuvant
4

References

(Supplied by CrossRef)

A Jemal et al.
CA Cancer J Clin 2011

BB Aggarwal et al.
Biochem Pharmacol 2006

F Kamangar et al.
J Natl Cancer Inst 2006

S Suerbaum et al.
N Engl J Med 2002

LM Coussens et al.
Nature (Lond) 2002

F Kamangar et al.
Cancer Epidemiol Biomarkers Prev 2006

RM Peek Jr et al.
Nat Rev Cancer 2002

I Hitzler et al.
J Immunol 2012

EM El-Omar et al.
Nature (Lond) 2000

EM El-Omar et al.
Gastroenterology 2003

JK Tarlow et al.
Hum Genet 1993

Similar Publications